| Bioactivity | Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome[1][2]. |
| Invitro | Lanreotide (BIM 23014) (100 nM; 0-48 h) enhanced radiation-induced apoptosis[1].Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1].Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2]. Apoptosis Analysis[1] Cell Line: |
| Name | Lanreotide diTFA |
| CAS | 1024499-83-9 |
| Shortening | {d-2nal}-CY-{d-Trp}-KVCT-NH2 (Disulfide bridge: Cys2-Cys7) |
| Formula | C58H71F6N11O14S2 |
| Molar Mass | 1324.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Lanreotide diTFA
CAS: 1024499-83-9 F: C58H71F6N11O14S2 W: 1324.37
Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for t
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.